Products
Pre-made Idarucizumab benchmark antibody ( Fab, anti-Dabigatran therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-261
Pre-Made Idarucizumab biosimilar, Fab: Anti-Dabigatran therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-261-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-261-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-261-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-261-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Idarucizumab biosimilar, Fab: Anti-Dabigatran therapeutic antibody |
| INN Name | Idarucizumab |
| Target | Dabigatran |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | 4jn2:HL:BA/4jn1:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Boehringer Ingelheim |
| Conditions Approved | Blood coagulation disorders |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
<